Search Medical Condition
Please enter condition
Please choose location from dropdown

Daqing, China Clinical Trials

A listing of Daqing, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

Chinese Herbal Medicine and Micronized Progesterone for Live Births in Threatened Miscarriage

The causes of spontaneous miscarriage are diverse and comprise chromosomal, genetic, anatomical, immunological, hormonal, infectious and psychological factors, the other factors contribute to an increased risk include advancing paternal and maternal age and mothers with systemic diseases, such as diabetes or thyroid dysfunction. However, the incidence is difficult to determine …

Phase

0.0 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Safinamide as add-on Therapy in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing motor fluctuations while on stable doses of Levodopa (L-dopa) (alone or in combination with other anti-Parkinson drugs). Eligible patients are …

Phase

0.0 miles

Learn More »

Effects of Prior Induced Termination of Pregnancy on Complications and Pregnancy Outcomes.

A prospective multicenter cohort study to evaluate effects of prior induced termination of pregnancy on complications and pregnancy outcomes.

Phase N/A

0.0 miles

Learn More »

Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II

According to the Global Burden of Disease(GBD) Study 2016, China bears the greatest lifetime risk of stroke from 25-year-age onward. Minor ischemic events, including minor stroke and TIA, were major parts of stroke manifestations. Events (CHANCE) has shown that 21-day dual antiplatelet therapy (clopidogrel and aspirin) compared to aspirin alone …

Phase

0.0 miles

Learn More »

Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non cardioembolic ischemic stroke which occurs when a …

Phase

0.09 miles

Learn More »

Effect of Intravenous Metoprolol Combining RIPC on Myocardial Protection in STEMI Patients

This study is a multicenter randomized controlled clinical trial, and planning to enroll 1200 patients with anterior STEMI. At the first medical contactpatients who meet the inclusion/exclusion criteria are divided into different groups before reperfusion. Patients randomize into placbo, Metoprolol, RIPC and Metorolol+RIPC groups. Subsequently, the investigator conduct diagnosis and …

Phase

4.31 miles

Learn More »

OCT Registry in Patients With STEMI During PPCI

This is a prospective, multi-center, non-randomized, observational registry study of STEMI patients that require primary catheterization.The purpose of this registry is to investigate the clinical outcomes, safety and cost-effectiveness of intravascular OCT imaging in patients with STEMI undergoing primary PCI.The total duration of the study is expected to be 5 …

Phase N/A

4.31 miles

Learn More »

Incidence Rate of Heart Failure After Acute Myocardial Infarction With Optimal Treatment

the study aim to enroll 12000 acute myocardial infartion (AMI) patients, including ST-segment elevation myocardial infarction (STEMI) and non ST-segment elevation myocardial infarction (NSETMI), Patients were divided into two groups(optimized group and un-optimized group) according to treatment models they accepted in 20 reginally representative hosptials of China. whether optimizaed or …

Phase N/A

4.31 miles

Learn More »

Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

This study will evaluate the EZ/Ator fixed-dose combination (FDC) tablet (MK-0653C) as second line Low-Density Lipoprotein - Cholesterol (LDL-C) treatment in Chinese participants. The primary hypothesis is that MK-0653C 10/10 mg is superior to atorvastatin 20 mg in percent change from baseline in LDL-C to 12 weeks after treatment.

Phase

4.31 miles

Learn More »

Xuefu-Zhuyu Capsule for the Treatment of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome)

"Xuefu-Zhuyu capsule" (XFZY) is made from a classic Fangji "Xuefu-Zhuyu Decoction" in an ancient Chinese medical book "Yi Lin Gai Cuo" by Chinese physician Wang Qingren, which is the most representative formula for the treatment of "Qizhi-Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome). XFZY concludes 11 kinds of Chinese …

Phase

4.31 miles

Learn More »